Current and future therapies for hepatitis C virus infection.
Current and future therapies for hepatitis C virus infection.
复制标题
DOI：
10.1056/nejmra1213651
复制
发表时间：
2013-05-16
期刊：
影响因子：
--
通讯作者：
Ghany MG
中科院分区：
文献类型：
--
作者：
Liang TJ;Ghany MG
在发现丙型肝炎病毒(丙型肝炎病毒)仅20年后，这种慢性感染的大多数人现在有可能治愈，这种慢性感染不仅在美国，而且在世界范围内都带来了巨大的疾病负担。最近批准了两种专门抑制病毒复制的直接作用抗病毒药物，大大提高了病毒清除率，从最初的干扰素单一疗法的不到10%提高到目前疗法的70%以上。此外，许多针对病毒或宿主因素的其他药物正在开发中，其中一些几乎肯定会在未来几年获得批准。谁应该接受治疗以及用什么疗法治疗的问题将越来越复杂，需要认真考虑。随着治疗方法的改进，在全系统范围内识别和护理需要治疗的患者将是下一个挑战。由于大多数感染者不知道自己的诊断结果，疾病控制和预防中心最近建议对1945至1965年间出生的所有人进行丙型肝炎病毒筛查。预计在这样的筛查过程中，将发现大量人感染病毒；是否有可能治疗所有这些人尚不清楚。本文就丙型肝炎病毒感染的治疗现状和药物开发现状作一综述。
Only 20 years after the discovery of the Hepatitis C Virus (HCV), a cure is now likely for most people affected by this chronic infection, which carries a substantial disease burden, not only in the United States but also worldwide. The recent approval of two direct-acting antiviral agents that specifically inhibit viral replication has dramatically increased the viral clearance rate, from less than 10% with the initial regimen of interferon monotherapy to more than 70% with current therapy. Moreover, many other drugs targeting viral or host factors are in development, and some will almost certainly be approved in the coming years. The questions of who should be treated and with what regimen will be increasingly complex to address and will require careful consideration. As therapy improves, systemwide identification and care of patients who need treatment will be the next challenge. Because most infected persons are unaware of their diagnosis, the Centers for Disease Control and Prevention recently recommended screening for HCV all persons born between 1945 and 1965. It is anticipated that in the course of such a screening process, a large number of persons will be found to be infected with the virus; whether it will be possible to treat all these people is unclear. This article reviews the current therapy for HCV infection and the landscape of drug development.